Deborah Zhou

7PUBLICATIONS
14CO-AUTHORS
Molecular targetsPredictive and prognostic markersSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 07, 2026
Contemporary Chemotherapy Benchmarks for Molecularly Defined Advanced NSCLC: Reconstructed Individual Patient-Level Data of 22 Randomized Trials.

|Apr 16, 2025
Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non-Small Cell Lung Cancer.

Deborah Di-Xin Zhou, Janene Dalrymple, Danielle Klingberg

|Jan 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.

Rachel Woodford, Deborah Zhou, Peey-Sei Kok

|Apr 08, 2022
Left cheek sclerosing rhabdomyosarcoma and development of isolated free flap donor site metastasis.

Deborah Zhou, Vivek Bhadri, Peter Luk

|Feb 14, 2022
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer.

Rachel Woodford, Deborah Zhou, Sarah J Lord

|Jan 05, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survival.

Rachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok

Pageof 2

Frequent Collaborators

3 joint publications

Rachel Woodford

3 joint publications

Ian Marschner

2 joint publications

Peey-Sei Kok

2 joint publications

Sarah J Lord